Johnson & Johnson Darzalex shows efficacy in early-stage multiple myeloma

Myeloma multiplex leukemia cancer 3d color render illustration

Nemes Laszlo

  • A phase 3 study of Johnson & Johnson’s (NYSE:JNJ) Darzalex (daratumumab) showed that the monoclonal antibody is effective against a type of early-stage multiple myeloma.
  • Results from the Aquila trial, presented as an abstract at an American College of Hematology conference, found

Leave a Reply

Your email address will not be published. Required fields are marked *